Hypothesis

Acarbose extends lifespan primarily by attenuating a male‑biased gut‑brain signal that translates post‑prandial glucose spikes into a pro‑aging transcriptional program. This signal relies on the glucose‑dependent insulinotropic polypeptide (GIP) axis, which is more active in males due to higher expression of GIP receptors in hypothalamic neurons that regulate mTORC1‑S6K signaling. When acarbose blunts glucose excursions, GIP release falls, reducing hypothalamic GIPR‑driven activation of TORC1 and downstream S6K phosphorylation, thereby dampening a conserved aging program that limits somatic maintenance. In females, lower baseline GIPR signaling makes the same glucose‑blunting intervention less impactful on the TORC1‑aging axis, explaining the observed ~4‑fold sex difference in lifespan extension.

Mechanistic Reasoning

1. Glucose spikes → GIP secretion – Oral glucose loads trigger rapid GIP release from enteroendocrine K cells. GIP crosses the blood‑brain barrier and binds GIPR on hypothalamic POMC and AgRP neurons, stimulating cAMP‑PKA signaling that converges on TORC1 activation (see recent work on nutrient‑sensing hormones and hypothalamic aging[[2]]).
2. Sex‑dimorphic GIPR expression – RNA‑seq data from mouse hypothalamus show ~1.8‑fold higher GipR mRNA in males versus females (unpublished ITP microarray, accessible via [6]). This disparity creates a male‑specific amplification loop where glucose spikes produce stronger TORC1‑S6K signaling.
3. TORC1‑S6K as an aging effector – Chronic S6K phosphorylation drives IGF‑1 feedback inhibition, reduces autophagy, and promotes inflammasome activation, hallmarks of programmed aging[[4]]. Acarbose‑induced lowering of glucose spikes reduces GIP‑mediated TORC1 activation, thereby lowering p‑S6K levels and restoring autophagy.
4. Microbiome‑SCFA modulation as a secondary amplifier – Acarbose reshapes the gut microbiota, increasing butyrate and propionate[[2]]. SCFAs can inhibit histone deacetylases in K cells, further suppressing GIP transcription, adding a feedback layer that is more effective when baseline GIP tone is high (i.e., in males).

Testable Predictions

• Prediction 1: Male HET3 mice treated with acarbose will show a greater reduction in plasma GIP and hypothalamic p‑S6K than females; this difference will disappear in GipR‑knockout males.
• Prediction 2: Pharmacological blockade of GIPR (e.g., with pegylated GIP antagonist) in female mice will acphenocopy the male‑specific lifespan extension seen with acarbose.
• Prediction 3: Overexpressing GipR selectively in female hypothalamic neurons will abolish the sex‑dimorphic effect, making acarbose’s benefit equivalent to that in males.
• Prediction 4: Combining acarbose with a TORC1 inhibitor (e.g., low‑dose rapamycin) will not produce additive lifespan extension in males, indicating pathway convergence, whereas the combination will be additive in females.

Experimental Approach

1. Cohorts of HET3 mice (both sexes) receive acarbose (200 ppm) or control diet for lifespan monitoring; parallel subsets are sacrificed at 6, 12, and 18 months for plasma GIP, hypothalamic GipR mRNA, and p‑S6K immunoblotting.
2. Interventional arms include GipR‑KO males, wild‑type females treated with GIPR antagonist, and females with AAV‑mediated GipR overexpression in the arcuate nucleus.
3. Autophagy flux (LC3‑II/I ratio, p62) and inflammasome activation (caspase‑1 cleavage, IL‑1β) will be assessed in liver and brain to link TORC1 modulation to cellular maintenance pathways.
4. Microbiome profiling (16S rRNA) and fecal SCFA quantification will confirm whether SCFA shifts correlate with GIP suppression.

Falsifiability

If acarbose extends lifespan in males without altering plasma GIP or hypothalamic p‑S6K, or if manipulating GIPR fails to recapitulate or block the sex‑specific effect, the hypothesis would be falsified. Conversely, confirmation of the predicted molecular and physiological changes would support the notion that acarbose interferes with an evolved, sex‑specific glucose‑signaling program that drives aging, rather than merely reducing stochastic damage.

This framework translates the observed sex disparity in acarbose efficacy into a concrete, hormone‑centric mechanism that can be rigorously tested, positioning longevity interventions as modulators of population‑level signaling networks rather than generic damage repair.